Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases.

The Bone Microenvironment: a Fertile Soil for Tumor Growth. Curr Osteoporos Rep (2016) 0.78

Mechanisms of osteolytic and osteoblastic skeletal lesions. Bonekey Rep (2015) 0.77

Ex vivo construction of human primary 3D-networked osteocytes. Bone (2017) 0.76

The role of hematopoietic stem cell niche in prostate cancer bone metastasis. J Bone Oncol (2016) 0.75

Mineralization and non-ideality: on nature's foundry. Biophys Rev (2016) 0.75

Prostate cancer: Under pressure-physical force promotes tumour growth. Nat Rev Urol (2015) 0.75

Osteocytes and Skeletal Pathophysiology. Curr Mol Biol Rep (2015) 0.75

Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res (2016) 0.75

Circulating tumor cells in prostate cancer: Precision diagnosis and therapy. Oncol Lett (2017) 0.75

Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res (2017) 0.75

Ex vivo replication of phenotypic functions of osteocytes through biomimetic 3D bone tissue construction. Bone (2017) 0.75

Hypoxia and Bone Metastatic Disease. Curr Osteoporos Rep (2017) 0.75

NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41

The amazing osteocyte. J Bone Miner Res (2011) 5.32

Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 2.74

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69

Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res (1997) 2.55

The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84

Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate (2006) 1.76

A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J Biol Chem (2006) 1.52

The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm (2014) 1.33

Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone (2008) 1.32

Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem (2002) 1.28

CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol (2008) 1.25

CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol (2009) 1.18

The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res (2006) 1.17

Microfluidic enhancement of intramedullary pressure increases interstitial fluid flow and inhibits bone loss in hindlimb suspended mice. J Bone Miner Res (2010) 1.14

Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res (2003) 1.14

Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One (2010) 1.03

CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PLoS One (2012) 1.00

Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res (2014) 0.97

Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res (2008) 0.96

Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat (2005) 0.95

Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo. Ann Biomed Eng (2005) 0.92

The role of osteocytes in bone regulation: mineral homeostasis versus mechanoreception. J Musculoskelet Neuronal Interact (2002) 0.92

Additive Influence of Extracellular pH, Oxygen Tension, and Pressure on Invasiveness and Survival of Human Osteosarcoma Cells. Front Oncol (2013) 0.84

Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clin Cancer Res (2015) 1.47

Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. Mol Cancer Res (2017) 0.75

Abituzumab Targeting of AlphaV-class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res (2017) 0.75

Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression. J Cell Biochem (2019) 0.75